Navigation Links
BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
Date:3/9/2011

RALEIGH, N.C., March 9, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California.  The presentation is scheduled for Monday, March 14 at 9:00 A.M. Pacific Time.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Dr. Sirgo will focus on BDSI's product pipeline, with a particular focus on BEMA Buprenorphine for the treatment of chronic pain and opioid dependence.  

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, the presentation will be archived for 3 months.

About BioDelivery Sciences International

BioDelivery Sciences International (Nasdaq: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Not getting the right ... colitis, a new study suggests. Those who sleep ... hours per night may be more prone to developing ... researchers report. The study authors concluded that duration and ... among patients with inflammatory bowel diseases. "Both short ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... more genetic tests are developed that spot increased risks for ... more proactive about getting screened. But a new study ... change behavior: People who found out their genes doubled their ... with average risk to get screened. "It didn,t make ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... 2014 Hay House is pleased to announce ... Upgrade Your Life (Paperback; $10.82) written by the highly esteemed ... This book is meant to help readers of all ... recovery. , Recovery 2.0 is not the average self-help ... is a guide for what comes next. For ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... from the Howard Florey Institute in Melbourne have identified ... heroin addiction by manipulating the adenosine A2A receptor, which ... , Using mice specifically bred without the adenosine A2A ... these mice had a reduced desire to self-administer morphine; ...
... translational research grant program will fund STOP Diabetes, a ... STOP project is designed to reduce the risk for ... , The STOP Diabetes project was created by investigators ... address the alarming increase in lifestyle related metabolic diseases ...
... Nepstar,Chain Drugstore Ltd. (NYSE: NPD ) (,China ... China based on the number of directly,operated stores, ... Charity,Federation to organize a program to provide relief ... province, China. Specifically, the program is,designed to encourage ...
... WASHINGTON, May 14 Tonight, the American Red,Cross ... and,corporations whose outstanding dedication and commitment enables the,organization ... This national,recognition event, held at the historic American ... Service, will bring together members of,Congress, military leaders, ...
... part in an eight-month workplace initiative reported that headaches and ... cent and their use of painkillers halved, according to research ... also reported that pain levels were less severe at the ... researchers compared 169 staff in Turins registry and tax offices ...
... at 11:00 AM ET, LIVINGSTON, N.J., May 14 ... leader in advanced,injection technologies, today announced that the Company ... March 31, 2008 on Thursday,May 15, 2008., Milestone ... beginning,at 11:00 AM Eastern time, and invites all interested ...
Cached Medicine News:Health News:Research sheds new light on heroin addiction 2Health News:International Diabetes Federation gives grant to metabolic syndrome research project in Australia 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 3Health News:American Red Cross Hosts Heritage of Service Dinner 2Health News:Office initiative reduces headaches and neck and shoulder pain by more than 40 percent 2Health News:Office initiative reduces headaches and neck and shoulder pain by more than 40 percent 3Health News:Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: